Clinical trials: Transfusions
Blood Disease
The Combination of IVIG, Dexamethasone and a Megadose of PBSCs for Decreasing DSAs
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor.
- Trial name
- NCT06471478
- Testing
- intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Hematology department of the 920th hospital
Sickle Cell Disease, Thalassemia
Stem Cell Transplant for Hemoglobinopathy
This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies.
- Conditions
- Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia
- Trial name
- NCT00176852
- Testing
- Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
β-thalassemia, Ineffective Erythropoiesis
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment…
- Conditions
- β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia
- Trial name
- TRANSCEND (NCT03802201)
- Testing
- PTG-300
- Where
- 33 sites in United States, Greece and 7 more
- Volunteers
- 63 people
- Sponsor
- Protagonist Therapeutics, Inc.
Glucose Transporter Type 1 Deficiency Syndrome, GLUT1DS1
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome
Pathogenic mutations of the brain glucose transporter type I lead to glucose transporter deficiency syndrome (G1D), which is most often associated with medication-refractory epilepsy and movement dysfunction.
- Trial name
- NCT04137692
- Testing
- Red Blood Cell Transfusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
Platelet Transfusion Refractoriness
Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR
The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR…
- Trial name
- NCT05761457
- Testing
- Cryopreserved autologous platelet transfusion
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Neonatal Thrombocytopenia, Intraventricular Hemorrhage
Monitoring Outcome in Neonatal Thrombocytopenia
Rationale: Approximately 10% of neonates admitted to neonatal intensive care units develop a major hemorrhage. In an attempt to avert this severe complication various preventive measures have been implemented.
- Conditions
- Neonatal Thrombocytopenia, Intraventricular Hemorrhage, Platelet Transfusion
- Trial name
- MONET (NCT03110887)
- Volunteers
- 700 people
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Anemia, Neonatal, Intracranial Hemorrhages
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
The purpose of this study is to test the safety and effectiveness of a whole own (autologous) umbilical cord blood transfusion in the first 5 days after birth if the baby is born premature <34 weeks and developed anemia of…
- Conditions
- Anemia, Neonatal, Intracranial Hemorrhages, Necrotizing Enterocolitis, Respiratory Distress Syndrome, Newborn
- Trial name
- NCT02050971
- Testing
- Umbilical Cord Blood Infusion, Intravenous Infusion of Peripheral Blood or its Components
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Pomeranian Medical University Szczecin
Sickle Cell Disease
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.
- Trial name
- NCT07656415
- Testing
- Mitapivat
- Where
- 5 sites in United States
- Volunteers
- 159 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Sickle Cell Disease, Iron Overload
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
- Conditions
- Sickle Cell Disease, Iron Overload, Hemolytic Anemia
- Trial name
- NCT00110617
- Testing
- Deferasirox (ICL670), Deferoxamine (DFO)
- Where
- 59 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- Novartis Pharmaceuticals
Transfusion-dependent Iron Overload
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.
- Trial name
- NCT00171821
- Testing
- Deferasirox
- Where
- 97 sites in Australia, Austria and 21 more
- Volunteers
- 1,784 people
- Sponsor
- Novartis Pharmaceuticals
Preterm, Infant Death
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries- PreTerm
The goal of this multicenter, cluster-randomized, crossover trial is to determine if umbilical cord milking compared to early cord clamping will reduce in-hospital mortality in non-vigorous preterm infants born between 30 weeks…
- Trial name
- CORDMILK-PT (NCT06240715)
- Testing
- Umbilical cord milking
- Where
- 9 sites in India
- Volunteers
- 800 people
- Sponsor
- Nemours Children's Clinic
Patent Ductus Arteriosus
Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates
Patent ductus arteriosus (PDA) is a common problem in preterm babies. Recently there have been various studies for and against an association between thrombocytopenia and PDA.
- Trial name
- NCT03022253
- Testing
- Liberal platelet transfusion, Restrictive platelet transfusion, Paracetamol
- Where
- India
- Volunteers
- 44 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C
History of Hepatitis C in Volunteer Blood Donors
Hepatitis C is a disease of the liver caused by the Hepatitis C Virus (HCV). Patients with hepatitis C may feel well and show no signs or symptoms of being ill.
- Trial name
- NCT00001982
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Infectious Disease Screening
Multicenter Study on Detection Strategy of Infectious Diseases in Blood Transfusion
In the past ten years, nucleic acid detection technology has overcome the limitations of serological detection, reduced missed detections due to window period, occult infection, etc., and its application in the field of pathogen…
- Trial name
- NCT04471688
- Testing
- infectious disease screening
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Congenital Heart Disease in Children
Amotosalen and Platelet Transfusion in Pediatric Heart Surgery
High level of security during blood transfusion has been achieved by donor selection and pathogen detection using serology or direct identification.
- Trial name
- TransPédia (NCT05128084)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Acute Ebola Virus Disease
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
- Trial name
- NCT02295501
- Testing
- INTERCEPT Plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cerus Corporation
Preterm Infants, Anemia of Prematurity
Hepcidin Levels in Preterm Infants
A recently isolated peptide hormone, hepcidin, is thought to be the principal regulator of iron homeostasis. Hepcidin acts by limiting intestinal iron absorption and promoting iron retention in reticuloendothelial cells.
- Conditions
- Preterm Infants, Anemia of Prematurity, Neonatal Sepsis
- Trial name
- NCT01539356
- Where
- Israel
- Volunteers
- 62 people
- Sponsor
- Meir Medical Center
Beta Thalassaemia
Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)
OTL-300 is a gene therapy drug product consisting of autologous hematopoietic stem/progenitor cluster of differentiation (CD) 34+ cells genetically modified with a lentiviral vector (GLOBE) encoding the human beta globin gene.
- Trial name
- NCT03275051
- Testing
- Safety and Efficacy assessments
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS San Raffaele
Thalassemia, Beta
Long-term Follow-up Study of BHC001 for TDT
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
- Trial name
- NCT06314529
- Testing
- Assessments
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Bioray Laboratories
Graft Failure, Sickle Cell Disease
Allo HSCT for High Risk Hemoglobinopathies
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation…
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Trial name
- NCT06872333
- Testing
- Alemtuzumab, Total Body Irradiation, Cell Infusion
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota